Intra-Cellular Therapies PE Ratio 2013-2022 | ITCI

Current and historical p/e ratio for Intra-Cellular Therapies (ITCI) from 2013 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Intra-Cellular Therapies PE ratio as of May 25, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Intra-Cellular Therapies PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-25 56.67 0.00
2022-03-31 61.19 $-3.63 0.00
2021-12-31 52.34 $-3.50 0.00
2021-09-30 37.28 $-3.21 0.00
2021-06-30 40.82 $-3.05 0.00
2021-03-31 33.93 $-3.16 0.00
2020-12-31 31.80 $-3.24 0.00
2020-09-30 25.66 $-3.22 0.00
2020-06-30 25.67 $-3.06 0.00
2020-03-31 15.37 $-2.78 0.00
2019-12-31 34.31 $-2.68 0.00
2019-09-30 7.47 $-2.69 0.00
2019-06-30 12.98 $-2.82 0.00
2019-03-31 12.18 $-2.82 0.00
2018-12-31 11.39 $-2.84 0.00
2018-09-30 21.70 $-2.65 0.00
2018-06-30 17.67 $-2.42 0.00
2018-03-31 21.05 $-2.15 0.00
2017-12-31 14.48 $-2.12 0.00
2017-09-30 15.78 $-2.20 0.00
2017-06-30 12.42 $-2.37 0.00
2017-03-31 16.25 $-2.67 0.00
2016-12-31 15.09 $-2.69 0.00
2016-09-30 15.24 $-2.72 0.00
2016-06-30 38.82 $-2.93 0.00
2016-03-31 27.80 $-2.83 0.00
2015-12-31 53.79 $-2.91 0.00
2015-09-30 40.04 $-2.76 0.00
2015-06-30 31.95 $-2.07 0.00
2015-03-31 23.88 $-1.61 0.00
2014-12-31 17.65 $-1.06 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.373B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00